Biotech Values

[oldberkeley]

Again, the Phase 2 data was very strong and there are at least some reasons to believe that GSK simply screwed up the Phase 3 trial design (and not that drisa doesn't work). Obviously the odds are long given that GSK walked but I read today that RNA isn't yet finished analyzing the Phase 3 data.

I'm familiar with the argument that GSK screwed up the trial design, and that may be so. Let's agree it makes no logical sense for them to walk of that.

Let's also agree that big pharma makes mistakes, GSK certainly included. So they're either making another mistake by returning drisa to RNA, or they've seen enough of the data to conclude that further analysis is probably fruitless, much less new trials. This last possibility is what concerns me.

I wonder if RNA will present any new P3 data during their Thursday morning JPM presentation?